Clinical Trials for Glaucoma

It can take many years for a potential treatment for glaucoma to work its way from the laboratory to rigorous testing and finally, approval by the Food and Drug Administration (FDA). The process begins in the lab with basic investigations using cells and specially bred animal models. Next, translational research moves the therapy to the human setting. Finally, the drug is tested on humans in clinical trials divided into three phases, I, II and III. These trials are used to determine the safety and effectiveness of the drug on progressively larger numbers of people. Normally, if the results are positive in the first two phases, the therapy will proceed to Phase III. The data gathering, analysis and reporting that are necessary to complete these trials can take several years.

Those with glaucoma or even healthy individuals may want to consider participating in clinical trials. Each trial has its own protocol or set of guidelines, and volunteers must meet certain criteria to qualify for inclusion. Before making a decision, get as much information as possible about the trials, and think seriously about the benefits and risks of volunteering. Those who participate will have access to potential new treatments, as well as medical care, and they may help others with glaucoma. However, there may be side effects to the medications being tested or they may not be effective, and participation requires a certain time commitment.

The following websites contain information on clinical trials:

• View a full list of resources for clinical trials research.
• The Pharmaceutical Research and Manufacturers of America (www.phrma.org) provides access to a database that includes glaucoma medicines currently in clinical trials or at the FDA for review.
• The National Institute on Aging has a very helpful information concerning clinical trials and the elderly population.

Last Reviewed On: 09/11/09